Day One goes to the mar­ket for $150M as biotech kicks off NDA re­quest for pe­di­atric brain can­cer drug

Day One Bio­phar­ma­ceu­ti­cals will of­fer up more than 11.5 mil­lion shares to nab $150 mil­lion in gross pro­ceeds af­ter the biotech last month start­ed a rolling sub­mis­sion for its pe­di­atric brain can­cer drug, which had a fresh da­ta drop at last week­end’s AS­CO.

The Bris­bane, CA-based drug de­vel­op­er will al­so give in­vestors a chance to buy an­oth­er 1.73 mil­lion shares at the price of $13 apiece, which would send pro­ceeds up an­oth­er $22.5 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER